Chemotherapy Monitoring With Breast Computed Tomography (CT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00808041|
Recruitment Status : Completed
First Posted : December 15, 2008
Last Update Posted : July 23, 2015
|Condition or disease||Intervention/treatment|
|Breast Cancer||Device: Dedicated breast computed tomography imaging|
Before undergoing surgery to remove the tumor, it is common for breast cancer patients to first undergo chemotherapy or hormonal therapy. The main goal of the therapy is to reduce the size of the tumor before it is removed. Unfortunately, therapy response varies a lot between patients. The development of an effective therapy response monitoring method could reduce the time that a patient undergoes ineffectual therapy or unnecessary therapy after complete response.
Dedicated breast computed tomography (or breast CT), a new way of imaging the breast, has been introduced in the last few years. Breast CT is an x-ray exam that uses 3D imaging to show the breast in its real three dimensional shape. Combined with the use of special chemicals called iodine contrast enhancement, breast CT can provide images of both the anatomy and the blood flow in the breast. We propose to use breast CT to carefully monitor the response to therapy of breast cancer patients undergoing therapy before surgery.
|Study Type :||Observational|
|Actual Enrollment :||3 participants|
|Official Title:||Breast Cancer Chemotherapy Monitoring With Dedicated Breast Computed Tomography|
|Study Start Date :||July 2009|
|Primary Completion Date :||September 2012|
|Study Completion Date :||July 2015|
Breast cancer patients undergoing hormonal therapy before surgery.
Device: Dedicated breast computed tomography imaging
Pre- and post-contrast enhancement acquisition of breast CT images of tumor-containing breast every two months.
Other Name: Koning CBCT,Cone Beam Breast CT
- Tumor response [ Time Frame: Mid-treatment and post-treatment completion ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00808041
|United States, Georgia|
|Emory University Winship Cancer Institute|
|Atlanta, Georgia, United States, 30322|
|Principal Investigator:||Ioannis Sechopoulos, PhD||Emory University|